Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...
Some diseases are a result of the loss of specific cells, such as the loss of motor neurons in amyotrophic lateral sclerosis ...
He introduced ticket prices that couldn’t be beat, but asked fliers to pay extra for nearly everything, including water, ...
Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...
This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...
The University of Ghana (UG), in collaboration with Google Research Africa and the University College of London’s (UCL) ...
In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...
The funding will help support the Ontario Provincial ALS Program to meet the needs of the roughly 1,300 people in Ontario ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback